These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
186 related items for PubMed ID: 29959804
1. Prevalence and clinicopathological characteristics of lipomatous neurofibromas in neurofibromatosis 1: An investigation of 229 cutaneous neurofibromas and a systematic review of the literature. Rozza-de-Menezes RE, Brum CAI, Gaglionone NC, de Sousa Almeida LM, Andrade-Losso RM, Paiva BVB, Faveret PLS, da Silva AV, Siqueira OHK, Riccardi VM, Cunha KS. J Cutan Pathol; 2018 Oct; 45(10):743-753. PubMed ID: 29959804 [Abstract] [Full Text] [Related]
4. Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study. Cannon A, Chen MJ, Li P, Boyd KP, Theos A, Redden DT, Korf B. Orphanet J Rare Dis; 2018 Feb 07; 13(1):31. PubMed ID: 29415745 [Abstract] [Full Text] [Related]
5. Head circumference and anthropometric changes and their relation to plexiform and skin neurofibromas in sporadic and familial neurofibromatosis 1 Brazilian adults: a cross-sectional study. Basto DL, de Souza Vieira G, Andrade-Losso RM, Almeida PN, Riccardi VM, Rozza-de-Menezes RE, Cunha KS. Orphanet J Rare Dis; 2022 Sep 05; 17(1):341. PubMed ID: 36064430 [Abstract] [Full Text] [Related]
6. Cutaneous neurofibromas: Current clinical and pathologic issues. Ortonne N, Wolkenstein P, Blakeley JO, Korf B, Plotkin SR, Riccardi VM, Miller DC, Huson S, Peltonen J, Rosenberg A, Carroll SL, Verma SK, Mautner V, Upadhyaya M, Stemmer-Rachamimov A. Neurology; 2018 Jul 10; 91(2 Suppl 1):S5-S13. PubMed ID: 29987130 [Abstract] [Full Text] [Related]
8. Giant gluteal and vesical plexiform neurofibromas in a patient with neurofibromatosis type 1: a case report. Sassi I, Bouida MA, Hasnaoui A, Zemni I, Ben Dhieb T. J Med Case Rep; 2024 Jan 13; 18(1):15. PubMed ID: 38216958 [Abstract] [Full Text] [Related]
9. Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials. Cannon A, Sarin KY, Petersen AK, Pichard DC, Wolters PL, Erickson G, Lessing AJ, Li P, Röhl C, Rosser T, Widemann BC, Blakeley JO, Plotkin SR. Clin Trials; 2024 Feb 13; 21(1):67-72. PubMed ID: 37269078 [Abstract] [Full Text] [Related]
15. The effect of pregnancy on growth-dynamics of neurofibromas in Neurofibromatosis type 1. Well L, Jaeger A, Kehrer-Sawatzki H, Farschtschi S, Avanesov M, Sauer M, de Sousa MT, Bannas P, Derlin T, Adam G, Mautner VF, Salamon JM. PLoS One; 2020 Feb 13; 15(4):e0232031. PubMed ID: 32343738 [Abstract] [Full Text] [Related]
18. Occult neurofibroma and increased S100 protein in the skin of patients with neurofibromatosis type 1: new insight to the etiopathomechanism of neurofibromas. Karvonen SL, Kallioinen M, Ylä-Outinen H, Pöyhönen M, Oikarinen A, Peltonen J. Arch Dermatol; 2000 Oct 13; 136(10):1207-9. PubMed ID: 11030766 [Abstract] [Full Text] [Related]
19. [Neurofibromas in Type I Neurofibromatosis. Description of a clinical case and literature review]. Del Puerto C, Aspee M, Downey C. Andes Pediatr; 2022 Oct 13; 93(5):741-748. PubMed ID: 37906895 [Abstract] [Full Text] [Related]